Jerry St. Peter is the Chief Executive Officer and Board Director of Xequel Bio. Jerry manages and leads Xequel’s business operations, communicates on behalf of the company, guides the development of Xequel’s short, mid and, long term strategies, and galvanizes the vision across the organization.
Jerry brings over 30 years of specialty biopharma executive leadership impacting strategic planning, commercial operations, financial management, fundraising, business development, and overall general management. The hallmark and passion of his career is serving his shareholders, doctors, and colleagues.
Prior to joining Xequel, Jerry was the Chief Executive Officer and President for Santen, Inc., a global ophthalmic company focused on serious unmet treatment needs by developing innovative solutions that protect and restore vision. Before leading Santen, the company acquired Eyevance Pharmaceuticals in 2020 for $225mm, where Jerry was the Co-founder, Chief Executive Officer, and Board Director. Established in 2017, Eyevance was a Private Equity backed venture solely focused on ophthalmic diseases that affect millions of patients every day. Prior to co-founding Eyevance, Jerry was the Senior Vice President and Head of Sun Pharmaceuticals’ newly formed Ophthalmics division. Before Sun, he was the Executive Vice President and General Manager for Nicox’s Ophthalmic business in the United States and formerly served as the Senior Vice President and Head of the Ophthalmic division at Inspire Pharmaceuticals before Merck acquired Inspire for $450mm in 2011.
What Jerry loves most about Xequel Bio is working alongside like-minded entrepreneurs and brilliant scientists who “choose the extraordinary” every day. His personal interests include enjoying timeless moments with his wife and best friend, Jamie, and inspiring his amazing children to seize the day. When time allows, Jerry finds being at the beach, golfing, or cheering on his beloved New England Patriots quite relaxing.